Shasqi to Present Data Updates at Upcoming SITC and CTOS Meetings

Tags:   Phase 1   Oncology  

-Presentations include updated data from Phase 1 study of SQ3370 in patients with advanced solid tumors and nonclinical data on SQ3370 combined with cancer immunotherapies-

SAN FRANCISCO--(BUSINESS WIRE)--Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) platform, today announced upcoming presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, taking place virtually and in person in Washington, DC, on November 10–14, 2021, and at the Connective Tissue Oncology Society’s (CTOS) Annual Meeting, being held virtually on November 10–13, 2021. Shasqi will present updated data from its Phase 1 clinical study of SQ3370 in patients with advanced solid tumors, and nonclinical data on SQ3370 in combination with cancer immunotherapies.

“We look forward to these upcoming presentations where we will share the progress of our Phase 1 study, present data on the compatibility of SQ3370 treatment with a local immune response and increases in certain circulating immune cells, and review nonclinical evidence that our click-chemistry approach has additional potential when combined with other cancer therapies,” said José M. Mejía Oneto, M.D., Ph.D., Founder and CEO of Shasqi.

---

---

SITC Meeting:

CTOS Meeting:

CAPAC and SQ3370:

SQ3370 utilizes Shasqi’s proprietary CAPAC platform, a click chemistry-based approach that activates cancer drugs at the site of a tumor with decreased systemic toxicity. The investigational product is based on the chemical reaction between an attenuated trans-cyclooctene-modified protodrug and a tetrazine-modified biopolymer. The biopolymer is injected into the target tumor lesion, where it precisely activates an intravenously infused protodrug. Unlike traditional targeted therapies, the CAPAC platform is agnostic to tumor characteristics that can vary from patient to patient, such as biomarker expression and enzymatic activity.

About Shasqi:

Shasqi is a privately held, clinical-stage biotechnology company whose mission is to enable patients to beat cancer with tumor-localized therapies. Shasqi leverages its proprietary CAPAC Platform to develop precision oncology therapeutics designed to improve efficacy while decreasing systemic toxicity. Shasqi’s CAPAC Platform is highly modular and can be applied to a broad range of drugs that are otherwise limited by toxicity, enabling the exploration of therapeutic biology in ways that were not previously possible.

Contacts

Cory Tromblee media@shasqi.com

Cory Tromblee media@shasqi.com